A prospective, multicentre phase II study comparing the efficacy and safety of second-line masitinib + lomustine vs masitinib + irinotecan in patients with relapsed glioblastoma multiforme
Phase of Trial: Phase I/II
Latest Information Update: 25 Jun 2015
Price : $35 *
At a glance
- Drugs Masitinib (Primary) ; Irinotecan; Lomustine
- Indications Glioblastoma
- Focus Therapeutic Use
- 25 Jun 2015 According to an AB Science media release, this study did not pass the pre-planned statistical analysis to detect a superiority trend in overall survival between masitinib in combination with standard-of-care chemotherapy when compared against its relevant historical meta-analysis benchmark. Therefore, the indication will not be moved to phase III.
- 25 Jun 2015 Status changed from recruiting to completed, according to an AB Science media release.
- 04 Sep 2013 New trial record